Literature DB >> 7067725

Pharmacokinetics and metabolism of fosmidomycin, a new phosphonic acid, in rats and dogs.

T Tsuchiya, K Ishibashi, M Terakawa, M Nishiyama, N Itoh, H Noguchi.   

Abstract

The absorption, distribution, metabolism, and excretion of 3-(N-formylhydroxylamino) propylphosphonic acid monosodium salt (fosmidomycin), a new antibiotic, were investigated in rats and dogs after i.v. and oral dosing. After i.v. administration of 10 mg/kg of body weight, [14C]-fosmidomycin was excreted mainly in the urine (about 90% of dose within 72 h); and only a little was excreted in the expired air (14CO2) and bile of rats (less than 1% of dose), which suggested the absence of enterohepatic circulation. After oral administration of 10 mg/kg of body weight to rats, 34% and 61% of dose were excreted in the urine and faeces, respectively, suggesting about 30% gastro-intestinal absorption. No metabolites were found by autoradiography of the urine after thin layer chromatography. Radioactivity levels in the serum essentially agreed with the unchanged fosmidomycin levels determined by reverse isotope dilution method. [14C]-fosmidomycin was rapidly distributed in the tissues of rats, and was maintained in high concentration in the liver, kidneys, and bone. The serum level data after i.v. administration closely fitted a 3-compartment open model with first order kinetics after nonlinear least squares regression by NONLIN. The half-lives of the serum level curves for the early, midway, and terminal phases were: 0.13, 0.51, and 17.3 h, respectively in rats; and 0.44, 0.75, and 2.0 h, respectively in dogs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7067725     DOI: 10.1007/BF03189544

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  2 in total

1.  FR-31564, a new phosphonic acid antibiotic: bacterial resistance and membrane permeability.

Authors:  H Kojo; Y Shigi; M Nishida
Journal:  J Antibiot (Tokyo)       Date:  1980-01       Impact factor: 2.649

2.  In vitro and in vivo antibacterial activities of FR-31564, a new phosphonic acid antibiotic.

Authors:  Y Mine; T Kamimura; S Nonoyama; M Nishida; S Goto; S Kuwahara
Journal:  J Antibiot (Tokyo)       Date:  1980-01       Impact factor: 2.649

  2 in total
  11 in total

1.  Characterization and application of the Fe(II) and α-ketoglutarate dependent hydroxylase FrbJ.

Authors:  Matthew A DeSieno; Wilfred A van der Donk; Huimin Zhao
Journal:  Chem Commun (Camb)       Date:  2011-08-10       Impact factor: 6.222

2.  Specific Inhibition of the Bifunctional Farnesyl/Geranylgeranyl Diphosphate Synthase in Malaria Parasites via a New Small-Molecule Binding Site.

Authors:  Jolyn E Gisselberg; Zachary Herrera; Lindsey M Orchard; Manuel Llinás; Ellen Yeh
Journal:  Cell Chem Biol       Date:  2017-12-21       Impact factor: 8.116

Review 3.  Fosmidomycin for the treatment of malaria.

Authors:  Jochen Wiesner; Steffen Borrmann; Hassan Jomaa
Journal:  Parasitol Res       Date:  2002-11-30       Impact factor: 2.289

Review 4.  Biosynthesis of phosphonic and phosphinic acid natural products.

Authors:  William W Metcalf; Wilfred A van der Donk
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

5.  In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.

Authors:  Jochen Wiesner; Dajana Henschker; David B Hutchinson; Ewald Beck; Hassan Jomaa
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

6.  Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways.

Authors:  Stefan Baumeister; Jochen Wiesner; Armin Reichenberg; Martin Hintz; Sven Bietz; Omar S Harb; David S Roos; Maximilian Kordes; Johannes Friesen; Kai Matuschewski; Klaus Lingelbach; Hassan Jomaa; Frank Seeber
Journal:  PLoS One       Date:  2011-05-04       Impact factor: 3.240

7.  Molecular basis of fosmidomycin's action on the human malaria parasite Plasmodium falciparum.

Authors:  Tomonobu Umeda; Nobutada Tanaka; Yoshio Kusakabe; Masayuki Nakanishi; Yukio Kitade; Kazuo T Nakamura
Journal:  Sci Rep       Date:  2011-06-14       Impact factor: 4.379

8.  Synthesis of functionalized cinnamaldehyde derivatives by an oxidative Heck reaction and their use as starting materials for preparation of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors.

Authors:  Anneli Nordqvist; Christofer Björkelid; Mounir Andaloussi; Anna M Jansson; Sherry L Mowbray; Anders Karlén; Mats Larhed
Journal:  J Org Chem       Date:  2011-10-07       Impact factor: 4.354

Review 9.  Prodrugs for the treatment of neglected diseases.

Authors:  Man Chin Chung; Elizabeth Igne Ferreira; Jean Leandro Santos; Jeanine Giarolla; Daniela Gonçales Rando; Adélia Emília Almeida; Priscila Longhin Bosquesi; Renato Farina Menegon; Lorena Blau
Journal:  Molecules       Date:  2007-03-19       Impact factor: 4.411

10.  Lipophilic prodrugs of FR900098 are antimicrobial against Francisella novicida in vivo and in vitro and show GlpT independent efficacy.

Authors:  Elizabeth S McKenney; Michelle Sargent; Hameed Khan; Eugene Uh; Emily R Jackson; Géraldine San Jose; Robin D Couch; Cynthia S Dowd; Monique L van Hoek
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.